Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Carmustine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR known ✓ | P00390 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.53 |
| ▸ | PDE4A | P27815 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 3/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carmustine SCHEMBL2047318 | 1.00 | ALDH1A1 (1.00) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| Carmustine SCHEMBL5783727 | 0.94 | ALDH1A1 (0.89) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| Elmustine SCHEMBL93476 | 0.90 | ALDH1A1 (0.82) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| SCHEMBL20906025 | 0.90 | ALDH1A1 (0.82) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| SCHEMBL9856739 | 0.87 | BLM (0.76) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| SCHEMBL25309077 | 0.87 | ALDH1A1 (0.77) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| SCHEMBL19351409 | 0.87 | ALDH1A1 (0.77) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| SCHEMBL9856483 | 0.87 | ALDH1A1 (0.77) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| SCHEMBL10005923 | 0.87 | ALDH1A1 (0.77) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| Ditiomustine SCHEMBL607073 | 0.85 | ALDH1A1 (0.74) | ALDH1A1BLMPMP22MEN1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 159129 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| WO-2026107377-A1 | PHARMACOLOGICAL RE-ACTIVATION OF MUTANT PVHL | KARANICOLAS JOHN (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260137700-A1 | PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITOR AND DNA DAMAGE-INDUCING SUBSTANCE | SK BIOPHARMACEUTICALS CO LTD (KR) | 2026-05-21 | — | — | US | claimed |
| WO-2026102563-A1 | DISUBSTITUTED PYRIMIDOPYRROLE ANALOG AND USE THEREOF | 深圳湾实验室坪山生物医药研发转化中心 | 2026-05-21 | — | — | WO | claimed |
| US-20260139071-A1 | Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses | JANSSEN BIOTECH INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137650-A1 | MODULATORS OF RAR RELATED ORPHAN RECEPTORS (RORs) | 11949098 CANADA INC (CA) | 2026-05-21 | — | — | US | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| EP-0335966-A4 | VASOCONSTRICTIVE SUBSTANCES IN COMBINATION WITH CYTOTOXIC AGENTS. | MATRIX PHARMA INC (US) | 1990-02-20 | — | — | EP | claimed |
| EP-0349617-A1 | METHOD FOR DETECTING IMMUNE-MEDIATED CYTOTOXICITY | ONCOTECH INCORPORATED (US) | 1990-01-10 | — | — | EP | claimed |
| EP-0335966-A1 | VASOCONSTRICTIVE SUBSTANCES IN COMBINATION WITH CYTOTOXIC AGENTS | MATRIX PHARMACEUTICALS, INC. (US) | 1989-10-11 | — | — | EP | claimed |
| WO-1989006162-A1 | METHODS AND APPARATUS ASSESSING TUMOR RESISTANCE | ONCOTECH INCORPORATED (US) | 1989-07-13 | — | — | WO | claimed |
| WO-1989003995-A1 | METHOD FOR DETECTING IMMUNE-MEDIATED CYTOTOXICITY | ONCOTECH INCORPORATED (US) | 1989-05-05 | — | — | WO | claimed |
| WO-1989002734-A1 | VASOCONSTRICTIVE SUBSTANCES IN COMBINATION WITH CYTOTOXIC AGENTS | MATRIX PHARMACEUTICALS, INC. (US) | 1989-04-06 | — | — | WO | claimed |
| EP-0227593-A1 | Use of chelating agents | THE HOSPITAL FOR SICK CHILDREN (CA) | 1987-07-01 | — | — | EP | claimed |
| US-4600573-A | ANTITUMOR AGENTS | RESEARCH CORPORATION (US) | 1986-07-15 | — | — | US | claimed |
| US-4300557-A | Method for treating intraocular malignancies | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1981-11-17 | — | — | US | claimed |
| US-4028410-A | Process of preparing 1,3-bis(2-chloroethyl)-1-nitrosourea | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1977-06-07 | — | — | US | claimed |